Valeant Pharmaceuticals International Announces 2014 Annual Meeting Results
LAVAL, Quebec, May 21, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2014 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below:
Name | For | Withheld | Broker Non-Votes | ||||
Ronald H. Farmer | 251,288,239 | 908,255 | 21,179,009 | ||||
Colleen A. Goggins | 251,712,817 | 483,677 | 21,179,009 | ||||
Robert A. Ingram | 249,639,221 | 2,557,273 | 21,179,009 | ||||
Anders Lonner | 251,650,643 | 545,851 | 21,179,009 | ||||
Theo Melas-Kyriazi | 251,423,599 | 772,895 | 21,179,009 | ||||
J. Michael Pearson | 246,575,385 | 5,621,109 | 21,179,009 | ||||
Robert N. Power | 250,186,656 | 2,009,838 | 21,179,009 | ||||
Norma A. Provencio | 251,604,073 | 592,421 | 21,179,009 | ||||
Howard B. Schiller | 238,521,290 | 13,675,204 | 21,179,009 | ||||
Katharine B. Stevenson | 250,315,363 | 1,881,131 | 21,179,009 |
At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2015 annual meeting of shareholders; and approved the 2014 Omnibus Incentive Plan and the ratification and approval of the grants of 320,033 share units and 180,000 options which were made subject to the shareholder approval of the 2014 Plan.
The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
SOURCE Valeant Pharmaceuticals International, Inc.
Help employers find you! Check out all the jobs and post your resume.